27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Four thousand four hundred eighty-six participants were included (mean age 71.3 ± 4.7 years, 30% participants Aβ+, 59% female). 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
No model terms met the a priori cut-off beyond the base model, including device type, response input source (e.g. mouse, etc.), or session interference. 5 key findings →
Participants: 167 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this cohort, 28 participants developed Alzheimer's dementia, 5 frontotemporal dementia, 2 Lewy body dementia, and 2 vascular dementia during the follow-up. 5 key findings →
Participants: 56 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MEG 16-38Hz spectral power, particularly over parieto-occipital magnetometers, was significantly reduced in the AD progression group. 5 key findings →
Participants: 117 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In PD‐SCD, baseline CSF Aβ42 is associated with cognitive progression. 5 key findings →
Design: cohort study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The rate of reversion from MCI to normal cognition was 37.0% after 2 years and 32.9% after 12 years. 5 key findings →
Design: longitudinal study Participants: 1,262 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cross-sectional studies suggest a limited relationship between accelerated epigenetic aging derived from epigenetic clocks, and Alzheimer's disease (AD) pathophysiology or risk. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BIOFACE is a two-year study of clinical, cognition, and biomarkers that will shed light on the physiopathology and the potential utility of plasma and NPEs as non-invasive early diagnostic and prognostic biomarkers in people younger than 65 years. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MCI and dementia were common among survivors from the original ARIC cohort. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Both groups showed significant improvements in all cognitive function measurements (P<.001). 3 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
EGb 761 ® is currently recommended in multiple guidelines for the symptomatic treatment of MCI. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Computer-based cognitive training might have beneficial effects on the general cognitive functions in early stage of Alzheimer's dementia. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
We conclude that Aβ deposition is associated with a pattern of cortical thickness reduction consistent with AD prior to the development of cognitive impairment. 4 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source
Relative to CN participants, Obj-SCD was associated with faster amyloid accumulation and selective vulnerability of entorhinal cortical thinning, whereas MCI was associated with faster entorhinal and hippocampal atrophy. 5 key findings →
Participants: 747 Evidence: low
Full summary, score breakdown and related studies → Original source
BrainCheck was able to distinguish between diagnoses of dementia, MCI, and NC, providing a potentially reliable tool for early detection of cognitive impairment. 1 key finding →
Participants: 99 Evidence: low
Full summary, score breakdown and related studies → Original source
Web-based cognitive tests have potential for standardized screening in neurodegenerative disorders. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our results suggest that the ki:e SB-C is an objective, scalable, and reliable indicator of cognitive decline, fit for purpose as a remote assessment in clinical early dementia trials. 3 key findings →
Participants: 69 Evidence: low
Full summary, score breakdown and related studies → Original source
Both DELPHI analysis of network function and DTI analysis detected a significant decrease in connectivity, excitability, and WM integrity in the SCD group compared to healthy control (HC) subjects; a significant decrease was also noted for aMCI and Dementia groups compared to HC. 3 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
The use of EHRs for AD-related research is promising, and AD-BERT shows superior predictive performance in modeling MCI-to-AD progression prediction. 1 key finding →
Participants: 3,657 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma p-tau217 was accurate for discriminating between Core1+ and Core1- patients (area under the curve = 0.92) with an optimal cut-off value of 0.274 pg/mL, revealing good accuracy (86.29%), positive predictive value (PPV; 88.18%), and negative predictive value (NPV; 83.09%). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma amyloid-β (Aβ) was associated with brain Aβ deposition and Alzheimer's disease (AD) development. 4 key findings →
Participants: 449 Evidence: low
Full summary, score breakdown and related studies → Original source
Amnestic mild cognitive impairment (aMCI) is considered a prodromal stage of Alzheimer's disease (AD). 2 key findings →
Participants: 191 Evidence: moderate
Full summary, score breakdown and related studies → Original source
There is increasing evidence of different subtypes of individuals with mild cognitive impairment (MCI). 3 key findings →
Participants: 640 Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is a prodromal stage of dementia, and its early detection is critical for improving clinical outcomes. 5 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
This is the first study to investigate the effect of MAKSCog, an individualised CCT, specifically developed for people with different subtypes of MCI. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
9 of the 2,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →